Skip to content
RDL Network logo
Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin — Philippa Newell (2007) | RDL Network